If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

According to the National Capital Poison Center, a not-for-profit poison control organization, at least 85 drugs—including ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...